The ADAGIO study investigated whether rasagiline has disease-modifying effects in Parkinson's disease. In the original/primary analysis it was shown that 1mg of rasagiline showed some benefit, but that 2mg did not. The reason for this was difficult to explain but it raised a number of questions, such as:
1) Does the design of these trials allow you to determine whether the study is truly modifying the underlying disease process or not?
2) Does the drug in question (rasagiline) truly modify the underlying disease or is it just improving symptoms?
3) Are the right patients being selected into these trials?
The new, secondary analysis is available online at the Lancet Neurology site. http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(11)70073-4/abstract
This is the link to the primary analysis of the ADAGIO data, which was published in the New England Journal of Medicine in 2009.
ReplyDeletehttp://www.nejm.org/doi/full/10.1056/NEJMoa0809335